Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0K7NI
|
|||
Former ID |
DIB004503
|
|||
Drug Name |
ABT-RTA-408
|
|||
Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y] | Phase 2 | [1] | |
Company |
Abbvie; reata pharmaceuticals
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Nuclear factor erythroid 2-related factor 2 (Nrf2) | Target Info | Modulator | [2] |
KEGG Pathway | Protein processing in endoplasmic reticulum | |||
NetPath Pathway | IL5 Signaling Pathway | |||
WikiPathways | Oxidative Stress | |||
Transcriptional activation by NRF2 | ||||
NRF2 pathway | ||||
Nuclear Receptors Meta-Pathway | ||||
Aryl Hydrocarbon Receptor Pathway | ||||
Mesodermal Commitment Pathway | ||||
Aryl Hydrocarbon Receptor | ||||
Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | ||||
Arylhydrocarbon receptor (AhR) signaling pathway |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT02142959) RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE. U.S. National Institutes of Health. | |||
REF 2 | National Cancer Institute Drug Dictionary (drug id 756624). |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.